Abdominal tissue concentrations and penetration of carboplatin in a HIPEC procedure ‒ assessment in a novel porcine model.
carboplatin
hyperthermic intraperitoneal chemotherapy
microdialysis
pharmacokinetics
Journal
Pleura and peritoneum
ISSN: 2364-768X
Titre abrégé: Pleura Peritoneum
Pays: Germany
ID NLM: 101710063
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
20
02
2022
accepted:
03
05
2022
entrez:
26
9
2022
pubmed:
27
9
2022
medline:
27
9
2022
Statut:
epublish
Résumé
Peritoneal dissemination from intraabdominal cancers is associated with poor prognosis and rapid disease progression. Hyperthermic intraperitoneal chemotherapy (HIPEC) is an antineoplastic treatment, which has improved survival and recurrence-free survival, but little is known about the acquired chemotherapy concentrations in local tissues. The aim of this study was to assess concentrations of carboplatin during and after HIPEC treatment dynamically and simultaneously in various abdominal organ tissues by means of microdialysis in a novel porcine model. Eight pigs underwent imitation cytoreductive surgery followed by HIPEC (90 min) using a carboplatin dosage of 800 mg/m No statistically significant differences in mean AUC Equal carboplatin distribution in abdominal organ tissues, detectable concentrations for at least 6 h after HIPEC completion, and a carboplatin penetration depth of minimum four mm were found. The present study proposes a new HIPEC porcine model for future research.
Identifiants
pubmed: 36159212
doi: 10.1515/pp-2022-0110
pii: pp-2022-0110
pmc: PMC9467902
doi:
Types de publication
Journal Article
Langues
eng
Pagination
117-125Informations de copyright
© 2022 Elisabeth K. Petersen et al., published by De Gruyter, Berlin/Boston.
Déclaration de conflit d'intérêts
Competing interests: The funding sources were not involved in study design, study execution, data analysis, interpretation, or scientific paper writing. Authors state no conflict of interest.
Références
Pleura Peritoneum. 2020 Sep 07;5(4):20200137
pubmed: 33575463
World J Gastroenterol. 2016 Jan 21;22(3):1114-30
pubmed: 26811651
Mater Sci Eng C Mater Biol Appl. 2020 Nov;116:111229
pubmed: 32806313
J Gastrointest Oncol. 2021 Apr;12(Suppl 1):S32-S44
pubmed: 33968424
Ann Surg. 2012 Dec;256(6):1084-8
pubmed: 22634898
Adv Drug Deliv Rev. 2000 Dec 15;45(2-3):125-48
pubmed: 11108971
Cancers (Basel). 2021 Jun 22;13(13):
pubmed: 34206563
Gynecol Oncol. 2009 Dec;115(3):362-6
pubmed: 19775736
Cancer Chemother Pharmacol. 1991;28(3):159-65
pubmed: 1855272
Ann Surg Oncol. 2020 Jan;27(1):232-239
pubmed: 31286314
Mol Neurobiol. 2017 Jul;54(5):3506-3527
pubmed: 27189617
Curr Cancer Drug Targets. 2002 Sep;2(3):209-26
pubmed: 12188908
Gynecol Oncol. 2007 Jul;106(1):207-10
pubmed: 17498782
Eur J Pharmacol. 2014 Oct 5;740:364-78
pubmed: 25058905
J Surg Oncol. 2014 Dec;110(8):970-5
pubmed: 25171494
Cancer Chemother Pharmacol. 1988;21(1):57-60
pubmed: 3277734
Ann N Y Acad Sci. 1958 Apr 24;68(3):1097-102
pubmed: 13627760
Gland Surg. 2020 Aug;9(4):1140-1148
pubmed: 32953629
J Clin Pharmacol. 2007 May;47(5):589-603
pubmed: 17442685
N Engl J Med. 2018 Jan 18;378(3):230-240
pubmed: 29342393
Cancers (Basel). 2019 Jan 11;11(1):
pubmed: 30641919
Gynecol Oncol. 2016 Jan;140(1):36-41
pubmed: 26546964
World J Gastroenterol. 2008 Feb 28;14(8):1159-66
pubmed: 18300340
Cancer Chemother Pharmacol. 1999;43(2):106-14
pubmed: 9923815
Cancer Lett. 1990 May 30;51(2):109-17
pubmed: 2344588
J Clin Pharmacol. 2002 Jul;42(7):762-73
pubmed: 12092743
Vet Pathol. 2012 Mar;49(2):344-56
pubmed: 21441112
Nucleic Acids Res. 2018 Jan 4;46(D1):D994-D1002
pubmed: 30053271
Clin Pharmacokinet. 2005;44(9):895-913
pubmed: 16122279
Gynecol Oncol. 2005 Apr;97(1):10-5
pubmed: 15790431
PLoS One. 2014 Sep 17;9(9):e103988
pubmed: 25230021
Drug Metab Dispos. 2018 Nov;46(11):1712-1724
pubmed: 30171162